Group 1 - The core viewpoint of the articles highlights the strong performance of He Yu-B (02256), a research-driven biopharmaceutical company focused on innovative drug development for small molecule precision oncology and immunotherapy, with a notable stock price increase of 6.7% on August 5 [1][3] - He Yu-B has five projects currently in clinical stages, aiming to address unmet needs of cancer patients globally through differentiated therapies supported by a robust R&D platform and team [1] - For the fiscal year 2025 mid-term report, He Yu-B reported total revenue of 612 million RMB and a net profit of 328 million RMB, with a year-on-year increase in attributable profit to shareholders of 58.84%, resulting in basic earnings per share of 0.53 RMB [2]